Dehydroepiandrosterone Feeding Prevents Aortic Fatty Streak Formation and Cholesterol Accumulation in Cholesterol-fed Rabbit

Yadon Arad, Juan J. Badimon, Lina Badimon, Wylie C. Hembree, and Henry N. Ginsberg

The concentration of dehydroepiandrosterone sulfate (DHEA-S) in human plasma is higher than any other steroid. Recent evidence has suggested an inverse relationship between plasma DHEA levels and the development of coronary atherosclerosis in humans. We used the cholesterol-fed rabbit model to investigate whether DHEA feeding would diminish aortic fatty streak formation in this model. Fifteen New Zealand White rabbits were fed rabbit chow supplemented with 0.5% cholesterol (wt/wt). Seven animals were, in addition, fed DHEA, 0.5% of diet (wt/wt). Animals were sacrificed after 2 months, and the aortic involvement with fatty streaks was evaluated by computerized planimetry of Sudan IV-stained aortas and by chemical analysis of aortic wall lipids. Compared to controls, DHEA-fed animals had similar plasma levels of total, very low density lipoprotein (VLDL), low density lipoprotein (LDL), and high density lipoprotein (HDL) cholesterol, corticoids, and estrogens. DHEA-fed animals had higher plasma levels of total, VLDL, and LDL triglycerides and lower HDL triglycerides than did controls. DHEA feeding resulted in 30% and 40%, respectively, inhibition of fatty streak formation by chemical analysis and planimetry. We conclude that DHEA feeding inhibits the development of aortic fatty streaks in cholesterol-fed rabbits, independent of changes in plasma total and LDL cholesterol levels or DHEA conversion to estrogens or corticoids.

(Arteriosclerosis 9:159–166, March/April 1989)

Dehydroepiandrosterone (DHEA) and its sulfate ester, DHEA-S, are weak androgens produced primarily by the adrenal gland. Although their serum concentrations far exceed those of any other adrenal product, their physiological roles have not been determined. In plasma, the majority of the hormone is present in the sulfated form, the concentration of which is stable. DHEA, itself, has a rapid turnover rate and displays variable levels during the day. Since tissues contain steroid sulfatases,8 it is possible that DHEA-S serves as a reservoir for DHEA. Reported effects of dietary DHEA supplementation include protection against obesity and insulin resistance in genetically predisposed animals.2–4 A recent study indicated that administration of DHEA was associated with a reduction of body fat and plasma low density lipoprotein (LDL) cholesterol levels in healthy humans.6 Since hyperinsulinemia and central obesity,7 as well as elevated LDL cholesterol levels, are factors predisposing to increased risk of atherosclerosis, it is possible that DHEA might be antiatherogenic. Indeed, in a recent study, DHEA-S levels were inversely related to subsequent death from coronary disease in men.8

The cholesterol-fed rabbit model has been used previously to study the effects of various agents on the development of aortic atherosclerosis. This model does not completely simulate the development of disease in humans because the large dietary cholesterol load raises the cholesterol concentration in very low density lipoprotein (VLDL) remnants to a larger degree than in LDL.9,10,11 Nonetheless, the cholesterol-fed rabbit model has been used to study the effects of calcium channel blockers,12 propranolol,13,14 and β-blockers15,16 on atherosclerosis. The epidemiological observation relating DHEA levels to atherosclerosis in humans was extended to the cholesterol-fed rabbit model in a recent report by Gordon et al.17 In that study, aortic injury was first induced by an intra-aortic balloon. A reduction of 39% in the degree of fatty streak formation, as measured by cross-sectional plaque thickness, was demonstrated in animals fed both DHEA and cholesterol as compared to controls fed cholesterol alone for 11 weeks after injury. The balloon injury model, however, may not be relevant to human atherosclerosis in which overt injury need not occur. We now report a study of the effect of DHEA feeding on the occurrence of aortic fatty streak formation in cholesterol-fed rabbits, without induction of prior injury.
Methods

Animal Model

Adult New Zealand White rabbits (3.0 ± 0.5 kg body weight) were housed in the Animal Research facilities of the Mount Sinai Medical Center. They were individually caged in stainless-steel wire-bottomed cages, in a room controlled at 20°C ± 2°C temperature, 50%-±10% humidity, and a 12-hour light/dark cycle. This animal care facility is accredited by the American Association for Accreditation of Animal Care, and all procedures were reviewed and approved by the Institutional Animal Care and Use Committee.

Experimental fatty streak formation was induced by feeding the animals 140 g of a 0.5% (wt/wt) cholesterol-rich diet daily for 60 days. The atherogenic diet was prepared by spraying normal rabbit chow (HF# S326, Ralston Purina Company, St. Louis, MO) with cholesterol dissolved in chloroform and allowing the solvent to evaporate for 2 days.18 We previously demonstrated that feeding cholesterol to rabbits at that concentration results in 30% to 50% of the rabbit aorta being covered by fatty streaks in both male and female rabbits with no apparent sex differences18 (Badimon JL, unpublished observation). Water was provided ad libitum.

Experimental Design

In our study, the animals received the atherogenic diet (control group) or the atherogenic diet plus 0.5% (wt/wt) DHEA (DHEA-fed group). The DHEA, which was in powder form, was incorporated into the atherogenic diet by mixing. Both groups of animals were studied simultaneously, and the animals were sacrificed 8 weeks after the initiation of the atherogenic feeding. There were seven females and one male in the control group and six females and one male in the DHEA group.

Plasma Lipid Analysis

Blood samples were collected in EDTA (1.5 mg/ml) after a 12- to 16-hour fast before starting the diet, at 20 days, at 40 days, and at sacrifice for determination of total cholesterol, high density lipoprotein cholesterol (HDL), and total triglyceride levels. Plasma was immediately obtained by low-speed centrifugation at 4°C. Aliquots were separated and kept frozen at −70°C until assayed. Cholesterol concentration in plasma was determined by using a Beckman enzymatic kit (Dry Stat Beckman Instruments Incorporated, Carlsbad, CA). Triglyceride concentration in plasma was measured using an enzymatic kit (Seragen Diagnostics, Indianapolis, IN). Prestudy HDL cholesterol concentration was measured in plasma after precipitation of apolipoprotein (apo) B-containing lipoproteins by PEG-6000.20 The HDL isolation was performed on an aliquot of fresh plasma after which the samples were kept frozen until assayed. We have observed that measurement of HDL cholesterol level by the precipitation method in severely hypercholesterolemic rabbits may be inaccurate, probably because of contamination by VLDL and LDL (data not shown). Poststudy HDL cholesterol levels are therefore reported only for HDL obtained by ultracentrifugation (below).

Preparation and Isolation of Lipoproteins

Additional blood was collected at sacrifice and separated as described above. Sodium azide was added to the freshly prepared plasma (0.01%). EDTA (0.1%) was present in all solutions to prevent hydroperoxidative degradation of lipoproteins. Lipoproteins were obtained by sequential ultracentrifugation of normal rabbit plasma by using a Beckman ultracentrifuge (model L5-65) and a 50.3 Ti Beckman rotor. VLDL (d<1.006), intermediate density lipoprotein (IDL) plus LDL (IDL+LDL, 1.006<d<1.063), and HDL (1.063<d<1.21) lipoproteins were separated by solvent density according to standard procedures, adjusting densities with KBr.21

Morphological Evaluation of Fatty Streak Formation

At sacrifice, the rabbits were anesthetized with ketamine plus Rompun (5 and 35 mg/kg, respectively, given intramuscularly). The carotid artery was cannulated, and the animals were exsanguinated. After laparotomy and exposure of the aorta, the animals were killed by an overdose of anesthetic, and the aortas were perfused in situ with 0.2 M phosphate-buffered saline containing papaverine (60 mg/500 cc) at 37°C to avoid vasconstriction. The aortas were removed intact from the aortic arch to the iliac bifurcation and were stripped of all adventitial debris. Thereafter, they were cut lengthwise into two halves through a dorsal and ventral incision. Care was taken to dissect between the dorsal bifurcations so that the flow dividers were evenly split between the two halves. One half of each aorta was fixed in 10% buffered formalin, and the other half was processed for lipid analysis. The fixed aortas were stained by Sudan IV for visualization of sudanophilic plaques. After staining, the aortas were pinned open to flatten them. A template was then made for each aorta by tracing the outlines of the aorta and the atheromatous lesions on a clear plastic sheet. Each template was magnified (×2) and photographed. Morphometric measurements of the percentage of total aorta covered with lipid deposits was determined by computerized planimetry (Numonics 124 EM Image analyzer). Each of three blinded observers prepared a template for each aorta, and each then performed planimetric measurements on his own templates, as well as on those prepared by the other two observers. Intra-observer variation was less than 1%.

Since atherosclerotic lesions form at specific sites, such as the bifurcation points of branching vessels, we alternated between choosing the right or left half of each aorta for biochemical or morphological analysis, so as to diminish the effect of differences between the two halves and negate possible artifacts due to unequal sectioning.

Biochemical Analysis of Aortic Wall and Liver

Aortas (half) were homogenized at 4°C in 5 ml of 0.13 M Tris HCl (pH 7.4), 0.1% EDTA, and 0.01% NaN3 by using a Polytron homogenizer. The total lipids were extracted from the homogenates in 10 volumes of chloroform/methanol (2:1; vol/vol) containing 0.001% butylated hydroxytoluene as an antioxidant. A second extraction
with the Folin procedure was then carried out.29 The lipid extracts were dried under nitrogen and resuspended in isopropyl alcohol. The total triglyceride and total cholesterol levels were measured by the specific enzymatic assays utilized for plasma lipid analysis. Phospholipid determinations were done according to the method of Naito.30 The livers were homogenized and extracted as described above for the aortas. Total cholesterol and phospholipid levels were measured in the hepatic lipid extracts by the specific enzymatic assays noted above.

**Hormone Assays**

Plasma total DHEA (DHEA plus DHEA-S) levels were measured by a radiimmunoassay of whole plasma utilizing sheep anti-DHEA-S as the first antibody and donkey antishellfish antibody as the secondary antibody (Pantex division of Bio-Analysis Inc., Santa Monica, CA). This assay has an 85% cross reactivity with DHEA, 15% cross reactivity with androstenedione, and 11% cross reactivity with androstenedione. Plasma corticoids were measured by a competitive protein binding assay by using corticosteroid binding globulin from human serum previously assayed to contain <2.0 μg/dl cortisol. Plasma corticoids were extracted with MeCl2.31 Cortisol was used as tracer ligand, and unbound hormone was separated by adding Florisil (Floridin Company). Corticosterone and cortisol, the primary corticoids in the rabbit, exhibited parallel displacement curves. The assay sensitivity was 1 μg/dl. Plasma estrogens were assayed by radiimunoassay after extraction into ether. The antibody used was raised in sheep against 17β-estradiol bound to bovine serum albumin by our laboratory (WC Hembree) and exhibited 85% cross reactivity with estrone and 15%, with estradiol against 3H-estradiol. Bound and unbound hormone are separated by using dextran-coated charcoal. Assay sensitivity was 30 pg/ml. Intra-assay and interassay coefficient variations for the three assays were 5% to 10%. All samples were run in a single assay for each hormone.

**Statistical Analysis**

Results between the two groups were compared by using Student's t test and the nonparametric Wilcoxon sum-rank test. Differences between groups that reached significance by that t test were considered truly significant only if they were also significant by the Wilcoxon sum-rank test and only if no skewness was present (skewness is a measurement of deviation from normal distribution). If skewness was present, the differences were considered statistically significant only if skewness could be eliminated by exclusion of "outliers" while maintaining significance. The Wilcoxon sum-rank test was used to confirm significance because this test does not assume a normal distribution (which may be a problem with a small sample size). DHEA levels were compared using the t test on the natural log of the DHEA concentration. Differences were considered significant if p<0.05.

**Results**

No differences between groups were observed in total food intake, weight gain, hematocrit, or platelet count.

Plasma levels for total DHEA, estrogens, and corticoids after the high-cholesterol diet are shown in Table 1. While there was a trend toward higher total DHEA levels in DHEA-fed animals compared to controls, the difference between the two groups did not reach statistical significance (p=0.09) due to considerable individual variability and to a small rise in total DHEA levels even in control animals (data not shown). There were no differences in estrogen or in corticoid levels between the two groups after the high-cholesterol diet.

Plasma lipids are presented in Table 2. Both groups responded to the high-cholesterol diet with similar, marked
increases in plasma total cholesterol concentration compared to the prestudy levels (control rabbits from a mean of 43.3 mg/dl to 816.4 mg/dl, DHEA-fed rabbits from a mean of 55.0 mg/dl to 964.3 mg/dl). HDL cholesterol levels remained unchanged in both groups (controls from a mean of 24.4 mg/dl to 19.4 mg/dl, DHEA-fed rabbits from a mean of 19.5 mg/dl to 18.4 mg/dl). There were no differences in plasma total cholesterol or HDL cholesterol concentrations between the two groups either before or after the cholesterol feeding. Plasma lipid levels drawn at 20 and 40 days after initiation of the diet demonstrated similar rates of rise in plasma cholesterol between the two groups (data not shown). Plasma triglyceride levels in the two groups before the high-cholesterol diet were also comparable (see Table 2). Although the triglyceride level of the control group did not change after the high-cholesterol diet, the triglyceride levels of the DHEA-fed animals rose significantly (from a mean of 70.6 to 128.2 mg/dl) compared to the prestudy triglycerides of either group, and to the poststudy triglycerides of the control group (p<0.01 for all three).

We also studied the lipid distribution among the different classes of plasma lipoproteins after the high-cholesterol diet (Table 3). Both groups showed similar high concentrations of cholesterol in both VLDL and IDL+LDL, compared to the prestudy total cholesterol. After the high-cholesterol feeding, there were no differences between the two groups in cholesterol content in any of the lipoprotein fractions. However, both the VLDL and IDL+LDL fractions from the plasma of DHEA-fed animals contained significantly more triglycerides than did those fractions from the plasma of the control animals. In contrast, HDL of DHEA-fed animals contained significantly less triglyceride than that of control animals.

Aortic involvement with fatty streaks, as determined by computerized planimetry of Sudan IV-positive areas, is shown in Figure 1. Fatty streak involvement occurred mainly at branch points of the aortic arch and the thoracic aorta. The abdominal aorta was much less involved. Comparison of the mean fatty streak involvement of the aortas, expressed as a percentage of the total aortic area covered by fatty streaks, showed a statistically significant 40% reduction of plaque area in the DHEA-fed animals versus controls (34% in the control groups vs. 19% in the DHEA-treated group, p<0.01).

Figure 1. Extent of aortic atherosclerosis in dehydroepiandrosterone (DHEA)-fed and control animals after a high-cholesterol diet, as determined by planimetric measurements. The values are the percent of total aortic area that was positive for lipid accumulation by Sudan IV staining. Means and 95% confidence limits are represented by horizontal bars. The extent of atherosclerotic involvement was 40% less in the DHEA-fed rabbits (p<0.01). The data points (C, O) represent aortas from individual rabbits.

To verify this reduction in fatty streak involvement by an independent method, we performed a chemical analysis of lipids extracted from the aortic wall (Figure 2). This examination showed a statistically significant 30% reduction of total cholesterol deposition in the aortas of DHEA-fed animals as compared to the control animals (controls 12.7 mg/g tissue, DHEA-fed 8.9 mg/g tissue, p<0.02). In contrast, no differences were found in phospholipid or triglyceride deposition in the aortas of DHEA-fed animals versus controls.

The content of lipid in livers from treated and control rabbits is shown in Table 4. The livers from DHEA-fed animals had a slightly but significantly higher total cholesterol content (control 18.1 mg/g tissue, DHEA-fed

| Animals       | VLDL | IDL+LDL | HDL      |
|---------------|------|---------|----------|
|               | Chol | TG      | Chol     | TG      | Chol   | TG  |
| Control       |      |         |          |         |        |     |
| (n=8)         | 582±163.2 | 40.6±11.8 | 317.3±164.7 | 20.6±7.1 | 18.4±6.9 | 12.6±2.5 |
| DHEA-fed      | 727.3±173.6 | 74.9±32.8 | 298.6±123.8 | 36.4±11.6 | 18.4±11.8 | 9.7±1.7 |
| p values      | NS   | p<0.03  | NS       | p<0.01  | NS     | p<0.04  |

Table 3. Cholesterol and Triglyceride Concentration in Plasma Lipoproteins after High-Cholesterol Diet

Values are mg/dl, means±SD.

VLDL = very low density lipoprotein, IDL = intermediate density lipoprotein, LDL = low density lipoprotein, HDL = high density lipoprotein, Chol = cholesterol, TG = triglyceride, DHEA = dehydroepiandrosterone.
fatty streaks and the magnitude of aortic cholesterol deposition in the same animal (not shown), demonstrating that the effects observed were not due to artifacts of the dissection process.

There was no effect of DHEA on total plasma, VLDL, IDL+LDL, or HDL cholesterol concentrations. The high-cholesterol diet resulted in similar increases of total cholesterol, VLDL cholesterol, and IDL+LDL cholesterol in both groups, whereas HDL cholesterol did not change in either group. In contrast, DHEA feeding resulted in an increase in total VLDL and IDL+LDL triglyceride levels and a decrease in HDL triglycerides compared to controls. DHEA feeding also resulted in increased liver content of cholesterol compared to controls. Finally, DHEA feeding had no effect on plasma estrogen or corticoid concentrations.

These data are consistent with the recent report by Gordon et al.17 that DHEA feeding caused a 39% reduction of aortic involvement with fatty streaks in rabbits fed cholesterol after aortic injury. It is possible, however, that the observed results in that study were due to DHEA modification of postinjury processes.

We chose to look at a model that utilized high-cholesterol feeding without induction of aortic injury because we felt that this model more closely resembles the disease process in humans. The cholesterol-fed rabbit model has limitations as a model for human disease because: 1) the rise in cholesterol is, to a large degree, due to accumulation of β-VLDL as previously described,9,10,11 2) feeding diets high in cholesterol for short periods of time may not resemble the chronic human atherosclerotic process, and 3) most of the lipid deposition in the aorta in this model is in the form of cholescerin ester-enriched fatty streaks,24,25,26 which are presumed, but not proven, to be the precursors of the more complicated fibrous plaques seen in humans in association with myocardial infarction. The cholesterol-fed rabbit, however, has been used previously to study the effects of calcium channel blockers, probucol, and β-blockers on the development of fatty streaks. The extent of reduction in fatty streak formation seen with those agents ranged from zero27,28 to over 90%29 for calcium channel blockers, from 40% to 60% for probucol,13,14 and from 20% to 40% for some, but not all, β-blockers.15,16 The effects of DHEA feeding that we observed in this study were similar to those seen with those other agents. However, in contrast to those agents, DHEA is a naturally occurring hormone, suggesting that the effects we observed may be more relevant physiologically to human atherosclerosis.

The cholesterol-fed rabbit model has also been used to study the effects of other naturally occurring hormones on the development of atherosclerosis. Glucocorticoids have been found to reduce aortic cholesterol accumulation and aortic 3H-thymidine uptake in cholesterol-fed rabbits.30,31 In humans, however, elevated cortisol levels are associated with increased atherosclerosis.32 It has also been shown that estrogens reduce the development of fatty streaks in cholesterol-fed rabbits.33,34 This may indeed be relevant to human atherosclerosis, since estrogens are thought to be protective against atherosclerosis in females.35 In our study, however, there were no differences in either plasma corticoids or plasma estrogen levels between the two groups.

---

**Figure 2.** Cholesterol, triglyceride, and phospholipid concentrations (mg/g tissue) of the aortas of control and dehydroepiandrosterone (DHEA)-fed animals were determined after a high-cholesterol diet as described in the Methods section. There was 30% less cholesterol in the aortas of DHEA-fed rabbits (p<0.02). There were no differences between the groups in the amount of either triglyceride or phospholipid contained in the aortas. Horizontal bars represent ± SD.

**Table 4. Lipid Content in Livers after High-Cholesterol Diet**

| Animals          | Cholesterol | Phospholipids |
|------------------|-------------|---------------|
| Control (n=8)    | 18.1±2.1    | 15.6±2.2      |
| DHEA-fed (n=7)   | 22.1±2.5    | 17.0±1.7      |
| p value          | p<0.01      | NS            |

 יודעים que não há diferença significativa no conteúdo lipídico entre os dois grupos.

**Discussão**

Este estudo examinou o efeito do jejum de DHEA nos sintomas de aterosclerose em coelhos fedidos de colesterol. Utilizamos dois métodos objetivos: avaliação de aterosclerose e avaliação de estrias de ateroma. Foi encontrada que a alimentação de DHEA foi protegida contra o desenvolvimento de estrias de ateroma em coelhos fedidos de colesterol. Após a alimentação de colesterol, as crianças alimentadas de DHEA desenvolveram 40% menos ateroma inflamatórios com estrias de ateroma, como determinado por planimetria computadorizada da aorta comparado com os controles. Seus aortas também contém 30% menos colesterol comparado com os animais controlados. Enquanto usamos apenas uma metade de cada aorta para a determinação, havia uma correlação direta entre a área coberta com a gordura.
The amount of DHEA that we fed the animals was large and was chosen because of the proven metabolic effects of the hormone in similar doses in previous investigations in animals. Unfortunately, the assay we used to measure DHEA in rabbits cannot distinguish between the base and the sulfated form in plasma. However, DHEA-S constitutes the majority of the hormone measured by this assay due to its higher concentration. Although there was a trend toward higher DHEA levels in DHEA-fed animals, the difference did not reach statistical significance. We did not observe an association between the blood levels of the hormone and the extent of fatty streak involvement in the aortas. It is possible that the large variation in the blood levels of DHEA that we observed was due to intra-animal variations in kinetics of gastrointestinal absorption or metabolism of DHEA, or to the effects of other factors, such as stress, which might alter the plasma concentration of DHEA. Such factors might confound an analysis of the relationship between DHEA blood levels and the prevention of atherosclerosis but not the analysis of the overall antithrombotic effects of DHEA, which may relate more to mean daily concentrations of the hormone. The rise in plasma DHEA that we observed was also smaller than that seen in humans after a smaller dose. This may have resulted from different levels of sulfatase activity in rabbits versus humans. The above notwithstanding, plasma levels of total DHEA in the treated animals were well within the range seen in normal humans.

The mechanism of action of DHEA in preventing fatty streak formation in the cholesterol-fed rabbit is not known. DHEA feeding to animals modifies several parameters that are considered to be risk factors for atherosclerosis. Thus, it has been shown that DHEA feeding to animals that are genetically predisposed to diabetes and obesity (e.g., the BL/6 mouse and the Zucker rat) will prevent obesity, reduce parametrial and peritoneal (central) fat, and prevent the development of insulin resistance and overt diabetes.3,4,5 We have no data to suggest similar effects during our short-term feeding protocol. DHEA feeding to animals has also been shown to retard the development of carcinogen-induced tumors36,37 and to reduce the spontaneous development of breast cancer in genetically predisposed animals.38 Whether this antiproliferative activity may extend to the effects of growth factors, such as platelet-derived growth factor, in the arterial vessel wall is unknown.

It is possible that the antithrombotic effect of DHEA in our study was related to the changes observed in lipoprotein triglyceride concentrations. Nordoagard et al.39 demonstrated that larger triglyceride-enriched VLDL may not pass through the endothelium, thus rendering them nonatherogenic. However, in that study, the VLDL triglyceride levels were much higher than those levels in our study. Furthermore, polyacrylamide gradient gel electrophoresis of the plasmas of our rabbits failed to show a difference between the groups in terms of mean β-VLDL size, partly because of the wide distribution of VLDL particle sizes in each rabbit after cholesterol feeding (data not shown). Conversely, triglyceride-rich LDL are thought to be associated with increased risk for developing atherosclerosis.40 In our study, however, the IDL+LDL of both groups contained similar, high levels of cholesterol, whereas “triglyceride-enriched LDL” are usually small, relatively cholesterol-poor particles.

We also found that DHEA feeding led to a slightly higher cholesterol content in the liver. The implication of this finding is unclear at this time, particularly in view of the similar plasma total cholesterol levels in the two groups of rabbits.

Regardless of the mechanism involved, our data may be of interest in relation to previous observations concerning DHEA and DHEA-S levels in humans. These include the demonstration that both DHEA and DHEA-S levels, as well as their responses to adrenocorticotropic hormone and corticosterone-releasing hormone, fall with age in both men and women, so that the levels of these androgens at age 70 are only 10% of the peak at age 25.41,42,43 This age-related decline is not seen in other steroids. DHEA levels have been found to be inversely related to LDL cholesterol concentrations in pretreatment44 and in anencephalic fetuses who are hypogonadal.45 In addition, the 24-hour urinary DHEA-S levels were inversely related to blood cholesterol concentrations in industrial workers.46 DHEA feeding to humans resulted in no change in serum cholesterol in one study47 but was associated with decreased LDL cholesterol levels in another study.5

While all of the above-noted associations support the epidemiological data indicating that DHEA-S levels were inversely correlated to subsequent death from atherosclerosis in humans, the one published study of DHEA levels in patients undergoing coronary angiography did not demonstrate differences in plasma DHEA concentrations between patients with positive and those with negative angiograms.48 On the other hand, we (Arad Y, Littenberg B, and Kluger J, unpublished data) and others49 have found higher DHEA levels in patients with negative coronary angiograms compared to patients with angiographically demonstrated coronary disease.

In summary, we have demonstrated that dietary DHEA supplementation significantly reduces the formation of Sudan IV-stainable fatty streak lesions and the accumulation of cholesterol in the aortas of cholesterol-fed rabbits. This finding, together with previous studies in both animals and humans, suggests an antithrombotic activity for DHEA, DHEA-S, or one of their metabolites. Further studies of the action of DHEA on cells of the arterial wall seem warranted.

Acknowledgments

We wish to express our gratitude to DeWitt S. Goodman for his critical comments and suggestions, to Linda Martinez for her secretarial assistance, and to Jimmy Lopez, Efrem Mogilski, and Livi Rappaport for technical support.

References

1. Nieschlag E, Lorlaff DL, Ruder HJ, Zucker IR, Kirschner MA, Lipsent MB. The secretion of dehydroepiandrosterone and dehydroepiandrosterone sulfate in man. J Endocrinol 1973;57:123-134
2. Hobkirk R. Steroid sulfoconjugates and steroid sulfates: characteristics and biological roles. Can J Biochem Cell Biol 1985;63:1127-1144
DHEA FEEDING IN CHOLESTEROL-FED RABBITS

Ard et al. 165

3. Coleman DL, Schwartz RW, Leiter EH. Effect of genetic background on the atherogenic effect of dehydroepiandrosterone (DHA) on cholesterol and ester mutants and in aged normal mice. Diabetes 1986;35:163-163

4. Shepherd A, Cleary MP. Metabolic alterations after dehydroepiandrosterone treatment in Zucker rats. Am J Physiol 1984;248:E55

5. Tagliatela AR, Davis JR, Truchon S, Van Hamont N. Effects of dehydroepiandrosterone sulfate on metabolism, body weight and composition of male and female rats. J Nutr 1986;116:1177-1183

6. Nester JE, Barasch CI, Cole RN, Blackard WD. Dehydroepiandrosterone reduces serum low density lipoprotein levels and body fat but does not alter insulin sensitivity in normal man. J Clin Endocrinol Metab 1986;56:57-61

7. Stem MP, Haffner SM. Body fat distribution and hyperinsulinemia as risk factors for diabetes and cardiovascular disease. Arteriosclerosis 1985;6:123-160

8. Barrett-Connor E, Khaw K, Yen S. A prospective study of dehydroepiandrosterone sulfate, mortality, and cardiovascular disease. N Engl J Med 1985;315:1519-1524

9. Brecher P, Chobanian AV, Small D, et al. Relationship of an abnormal plasma lipoprotein to protection from atherosclerosis in the cholesterol-fed diabetic rabbit. J Clin Invest 1983;72:1553-1562

10. MacKinnon AM, Savage J, Gibbons RA, Barter PJ. Secretion of apolipoprotein E-enriched very low density lipoproteins by the liver of cholesterol-fed rabbits. Atherosclerosis 1985;54:145-155

11. Kroon PA, Thompson GM, Chao Y. β-very low density lipoproteins in cholesterol-fed rabbits are of hepatic origin. Atherosclerosis 1986;56:323-329

12. Weisneth DB, Heldin JG. Antiatherogenic properties of calcium antagonists. Am J Cardiol 1987;59:163B-172B

13. Kritchevsky D, Singer D, Klurfeld DM. Influence of hypercholesteremic drugs on aortic cholesterol ester in rabbits. Pharmacol Res Commun 1986;16:525-527

14. Tawara K, Ishihara M, Ogasawara H, Tomikawa M. Effect of probucol, pantethine and their combinations on serum lipoprotein metabolism and on the incidence of atheromatous lesions in the rabbit. J Pharmacol 1988;41:211-222

15. Whittington-Coleman PJ, Carrier O J, Douglas BH. The effects of probenecid on cholesterol-induced atheromatous lesions. Atherosclerosis 1973:18:337-345

16. Kaplan JR, Manuck SB, Adams MR, Clarkson TB. The effects of beta-adrenergic blocking agents on atherosclerosis and blood pressure. Eur Heart J 1987;9:928-944

17. Gordon GB, Bush DE, Welman HF. Reduction of atherogenesis by administration of dehydroepiandrosterone. A study in the hypercholesterolemic New Zealand White rabbit with aortic intimal injury. J Clin Invest 1986;82:712-720

18. Badimon JJ, Kottke B, Chen TC, Chen L, Mao SJT. Quantification and immunolocalization of apolipoprotein E in experimental atherosclerosis. Atherosclerosis 1986;61:57-66

19. Badimon JJ, Badimon L, Ellea S, Fuster V. Effect of high-density lipoproteins on experimental atherosclerosis. In: Gallo LL, ed. Cardiovascular disease. New York: Plenum Publishing, 1987:4430-4454

20. Izzo C, Grillo F, Murador F. Improved methods for determination of high density lipoprotein cholesterol. Isolation of high density lipoproteins by use of polyethylene glycol-6000. J Clin Chem 1969;20:27-37

21. Havel RJ, Eder HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 1955;34:1345-1355

22. Polich L, Leeds M, Sturman GM. A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 1952;215:497-505

23. Naft HK. Modification of the flakle and SubbaRow method for total phospholipid in serum. Clin Chem 1973;21:1154-1156

24. Newman HA, Ziferbim DB. Accumulation of lipid and non-lipid constituents in rabbit atheroma. J Atheroscler Res 1964;4:261-271

25. Day AJ, Wahlquist ML. Uptake and metabolism of H14C-labeled oleic acid by atherosclerotic lesions in rabbit aorta. Cite Res 1986;23:777-778

26. Severson DL, Lefler T. Characterization of cholesterol ester hydrolase activity in rabbit and guinea pig aortas. Atherosclerosis 1979;64:131-132

27. Diclaud A, Celiniin AD, Britt AL, Jackson LR, Schwartz A. Effect of a sustained release formulation of thelazolam on the development of atherosclerosis in cholesterol-fed rabbits. Atherosclerosis 1987;75:199-205

28. Stender S, Stender I, Nordsethbaard B, Kjeldsen K. No effect of rifampicin on atherosclerosis in cholesterol-fed rabbits. Arteriosclerosis 1984;4:399-399

29. Sugano M, Makishima Y, Kamehda T, et al. Suppression of atherosclerosis in cholesterol-fed rabbits by diltiazem injection. Atherosclerosis 1986;5:237-241

30. Cavalero C, Di Tondi U, Mingazzini P, et al. Cell proliferation in the atherosclerotic plaques of cholesterol-fed rabbits. Atherosclerosis 1986;56:323-329

31. Bailey JM, Wastost R, Bombert AT, Randazzo R. Antithrombotic drugs in experimental atherosclerosis. Atherosclerosis 1986;51:299-306

32. Troxler RG, Sprague EA, Albanese RA, Fuchsa R, Thompson AJ. The association of elevated plasma colestol and early atherosclerosis as demonstrated by coronary angiography. Atherosclerosis 1977;26:151-162

33. Hough JL, Ziferboj DB. Effect of 17 Beta estradiol on aortic cholesterol content and metabolism in cholesterol-fed rabbits. Arteriosclerosis 1986;6:57-63

34. Kuslahwa RS, Hazzard WR. Exogenous estrogens attenuate dietary hypercholesterolemia and atherosclerosis in the rabbit. Metabolism 1986;35:359-364

35. Bush TL, Cowen LD, Barrett-Connor E, et al. Estrogen use and all-cause mortality. Preliminary results from the Lipid Research Clinic Program Follow-up Study. JAMA 1983;249:903-909

36. Moore MA, Themavti T, Tsuda H, Sato K, Ichihara A, ts N. Modifying effect of dehydroepiandrosterone on the development of hydroxy-d-Nonpropylisomerase-initiated lesions in the thyroid, lung, and liver of F344 rats. Carcinogenesis 1986;7:317-322

37. Nyce JN, Magee PN, Hergin GC, Schwartz AG. Inhibition of 1,2-dimethylhydrazine-induced colon tumorigenesis in BALB/c mice by dehydroepiandrosterone. Carcinogenesis 1984;5:57-62

38. Schwartz AG. Inhibition of spontaneous breast cancer formation in female C3H (A/He) mice by long-term treatment with dehydroepiandrosterone. Cancer Res 1979;39:1129-1132

39. Nordsethbaard BG, Stender S, Kjeldsen K. Severe hyperlipoproteinemia, large lipoproteins and protection against atherosclerosis. Scand J Clin Lab Invest (suppl) 1987;162:7-12

40. Teng B, Thompson GR, Sniderman AD, Forte TM, Krausa RM, Kwtaretovich PO Jr. Composition and distribution of low density lipoprotein fractions in hyperlipoproteinemia, normo- lipoproteinemia, and familial hypercholesterolemia. Proc Natl Acad Sci USA 1982;18:696-698

41. Smith MR, Rudd BT, Shirley A, et al. A radioimmunoassay for the estimation of serum dehydroepiandrosterone sulphate in normal and pathological sera. Clin Chir Acta 1975;56:5-13

42. Parker LR, Gral T, Pernig V, Skowronski R. Decreased adrenal androgen sensitivity to ACTH during aging. Metabolism 1981;30:901-904

43. Pavlov EP, Harman SM, Chandos GP, Loralux DL, Blackman MR. Responses of plasma adrenocorticotropic hormone, corticosteroids, plasma cholesterol and plasma corticosteron-releasing hormone in healthy aging men. J Clin Endocrinol Metab 1986;82:767-772

44. Parker CR, Simpson ER, Bilhelmer DM, Levano K, Carr BR, MacDondall PC. Inverse relation between low-density lipoprotein-cholesterol and dehydroepiandrosterone-sulphate in human fetal plasma. Science 1980;208:512
45. Parker CR Jr, Carr BR, Winkel CA, Casey ML, Simpson ER, Macdonald PC. Hypercholesterolemia due to elevated low density lipoprotein-cholesterol in newborns with anencephaly and adrenal atrophy. J Clin Endocrinol Metab 1983; 57:37–43

46. Lopez-S A, Wingo C, Herbert JA. Total serum cholesterol and urinary dehydroepiandrosterone in humans. Atherosclerosis 1976;24:471–481

47. Aldercreutz H, Kerstel J, Schaumann KO, Svanborg A, Vihko R. Plasma lipids and steroid hormones in patients with hypercholesterolemia or hyperlipidemia during dehydroepiandrosterone sulphate administration. Eur J Clin Invest 1972;2:91–95

48. Zumoff B, Troxler RG, O’Connor J, et al. Abnormal hormone levels in men with coronary artery disease. Atherosclerosis 1982;2:58–67

49. Harrington DM, Gordon GB, Achuff SC, et al. Dehydroepiandrosterone sulphate (DHEAS) and coronary artery disease (CAD). CVD Epidemiology Newsletter, Council on Epidemiology, American Heart Association 1988;3:11

Index Terms: dehydroepiandrosterone • atherosclerosis • cholesterol • rabbit • triglycerides • aorta • lipoprotein • planimetry • hormone